The Ischemia Modified Albumin In Diagnosing Ischemic New Events

Stopped early

Conditions studied: Heart Disease, Ischemic, Ischemia, Myocardial, Ischemic Heart Disease, Unstable Angina

In brief

The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.

Key facts

Study ID
NCT00355992
Run by
Inverness Medical Innovations
People needed
1250
Starts
2006-09-01
Expected to finish
2007-12-01
Last updated by the study team
2009-05-12

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.